World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
13230
World Ranking
3862
National Ranking
28

Overview

Gal Markel is affiliated with Tel Aviv University in Israel and has a research focus primarily in medicine and biochemistry, genetics, and molecular biology. Their work spans several subfields including oncology, molecular biology, immunology, pulmonary and respiratory medicine, and statistics and probability.

The scientist's research topics include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Health Systems, Economic Evaluations, Quality of Life
  • Melanoma and MAPK Pathways
  • Immune Cell Function and Interaction
  • Statistical Methods in Clinical Trials

Gal Markel has contributed to numerous publications, with a strong presence in well-known scientific journals and venues. Their frequent publication venues include:

  • The Lancet Oncology
  • Cancers
  • JAMA Network Open
  • Journal for ImmunoTherapy of Cancer
  • Bioinformatics

Some recent scientific papers by Gal Markel are:

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients, 2020, Science
  • MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma, 2020, OncoImmunology
  • Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma, 2020, Cancers
  • Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma, 2022, JAMA Network Open
  • Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy, 2021, Journal for ImmunoTherapy of Cancer

Gal Markel has collaborated extensively with several co-authors, reflecting a network of frequent scientific partnerships. These frequent co-authors include:

  • Tomer Meirson
  • David Bomze
  • Nethanel Asher
  • Jacob Schachter
  • Ronnie Shapira-Frommer

Best Publications

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

    Erez N. Baruch;Erez N. Baruch;Ilan Youngster;Guy Ben-Betzalel;Rona Ortenberg

  • Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

    Chamutal Gur;Yara Ibrahim;Batya Isaacson;Rachel Yamin

  • Characterization of the expression of MHC proteins in human embryonic stem cells

    Micha Drukker;Gil Katz;Achia Urbach;Maya Schuldiner

  • Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

    Michal J. Besser;Ronnie Shapira-Frommer;Avraham J. Treves;Dov Zippel

  • Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

    Tal I Arnon;Hagit Achdout;Ofer Levi;Gal Markel

  • Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

    Michal J. Besser;Ronnie Shapira-Frommer;Orit Itzhaki;Avraham J. Treves

  • CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells.

    Jacob Hanna;Ori Wald;Debra Goldman-Wohl;Diana Prus

  • Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

    Michal Harel;Rona Ortenberg;Rona Ortenberg;Siva Karthik Varanasi;Kailash Chandra Mangalhara

  • Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis

    Einav Shoshan;Aaron K. Mobley;Russell R. Braeuer;Takafumi Kamiya

  • Tumor and viral recognition by natural killer cells receptors.

    Tal I. Arnon;Gal Markel;Ofer Mandelboim

  • CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity.

    Gal Markel;Niva Lieberman;Gil Katz;Tal I. Arnon

  • Establishment and large-scale expansion of minimally cultured young tumor infiltrating lymphocytes for adoptive transfer therapy

    Orit Itzhaki;Einat Hovav;Yaara Ziporen;Daphna Levy

  • Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

    Hamzah Abu-Sbeih;David M. Faleck;Biagio Ricciuti;Biagio Ricciuti;Robin B. Mendelsohn

  • MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth

    Yael Nemlich;Eyal Greenberg;Eyal Greenberg;Rona Ortenberg;Rona Ortenberg;Michal J. Besser

  • Complexes of HLA-G Protein on the Cell Surface Are Important for Leukocyte Ig-Like Receptor-1 Function

    Tsufit Gonen-Gross;Hagit Achdout;Roi Gazit;Jacob Hanna

  • Triage and management of pericardial effusion.

    Massimo Imazio;Bongani M Mayosi;Antonio Brucato;Gal Markel

  • Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

    Merav Lidar;Merav Lidar;Eitan Giat;Daniela Garelick;Yuval Horowitz

  • Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.

    Michal J. Besser;Ronnie Shapira-Frommer;Avraham J. Treves;Dov Zippel

  • MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

    Ricardo A. de Azevedo;Ricardo A. de Azevedo;Einav Shoshan;Shanzhi Whang;Gal Markel

  • Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions

    Gal Markel;Dana Wolf;Jacob Hanna;Roi Gazit

  • Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.

    Noam Stern;Gal Markel;Tal I. Arnon;Raizy Gruda

Frequent Co-Authors

Jacob Schachter
Jacob Schachter Sheba Medical Center
Ofer Mandelboim
Ofer Mandelboim Hebrew University of Jerusalem
Iris Barshack
Iris Barshack Sheba Medical Center
Jacob H. Hanna
Jacob H. Hanna Weizmann Institute of Science
Richard S. Blumberg
Richard S. Blumberg Brigham and Women's Hospital
Arnon Nagler
Arnon Nagler Sheba Medical Center
Angel Porgador
Angel Porgador Ben-Gurion University of the Negev
Gideon Rechavi
Gideon Rechavi Sheba Medical Center
Dana G. Wolf
Dana G. Wolf Hebrew University of Jerusalem
Omry Koren
Omry Koren Bar-Ilan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare careers often require foundational nursing education. Many students explore options like accelerated RN to NP programs to fast-track their progression into advanced nursing roles that intersect with immunological sciences.

If you’re starting fresh without a nursing background, consider 12-month accelerated nursing programs online for non nurses. These intensive programs equip students with essential nursing skills in a condensed timeframe, making a nursing career more accessible while supporting future specialization.

For undergraduate students aiming to enter nursing quickly, the easiest ABSN programs to get into offer a streamlined path to earning a Bachelor of Science in Nursing. These programs balance accessibility with quality education, an excellent step before advancing to immunology-focused roles.

Additionally, for those seeking entry-level nursing positions, easy LPN programs to get into provide practical training and quick certification. This can serve as a stepping stone to more specialized healthcare careers connected to immunology.

Best Scientists Citing Gal Markel

Trending Scientists

Recently Published Articles